The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
Dr Leonardo Bruno Ribeiro Costa
President of Biosafety Intern Comission
Intervet do Brasil Veterinária Ltda (INTERVET)
Av. Sir Henry Wellcome 335, Prédio Administrativo, 1º andar, Ala
"E", Moinho Velho.
Cotia, São Paulo
Innovax®-ND, a recombinant vaccine that helps aid in the protection
of Newcastle and Marek's diseases in chickens. Innovax-ND utilizes
the herpesvirus of turkey (HVT) to carry Newcastle disease (ND)
antigens, which induce immunity against ND. HVT also protects
chickens against Marek's disease, which is caused by a herpesvirus
and results in tumors, high mortality and immunosuppression.
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
PB1 strain: non-virulent , non pathogenic strain of the HTV virus,
which is used as a vaccine for over two decades.
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Fusion protein gene - Newcastle disease virus - Newcastle disease virus, NDV
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
The INNOVAX® ND Vaccine is a recombinant HVT strain that contains a
gene that codes for the fusion protein (F-protein) of the Newcastle
Disease virus, directed by promoter derived from the Rous sarcoma
virus long terminal repeat sequence (LTR).
The gene was integrated into the host genome through homologous
recombination as follows:
1. The protein F coding sequence was obtained through cDNA
synthesis of genomic NDV, clone 30, RNA that was harvested and
purified from infected embryonated eggs.
2. The F-protein coding cDNA was isolated and cloned into the HVT
recombination vector pVECO4, which also contains the Rous
sarcoma virus LTR promoter, resulting in the pNDVO4 plasmid.
3. pNDVO4 plasmid DNA and HVT were co-transformed into chicken
embryo fibroblasts and incubated under conditions that favour
4. Selection of the recombinant virus was conducted by
immunofluorescence, to detect F protein expression. The resulting
strain was named HVT/NDV-F. Sequences of plasmids or markers were
not detected in the recombinant virus.
- Production of medical or pharmaceutical compounds (human or animal)
With the use of the Innovax ND vaccine, immunity against Newcastle
Disease starts at two weeks of age and lasts for at least of 60
weeks after one single dose of the vaccine. For Marek's Disease,
immunity starts at the fifth day of age and the vaccine lastes for
the whole period of risk.
The vaccine is administered to chicken embryonic eggs at 18 days of
incubation through the in ovo route, or to one day chicks
through subcutaneous injections.